Rare bone infection study aims to uncover best treatment paths
NCT ID NCT07665866
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 100 adults diagnosed with skull base osteomyelitis, a rare and serious bone infection near the ear and skull base. Researchers will track how often the infection returns or leads to death within 12 months. The goal is to gather real-world data to help standardize care for this poorly understood condition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better understand how this rare infection progresses and lead to more standardized treatment guidelines.
- What could go wrong
- This is an observational study, not testing a new treatment. It may not directly improve patient outcomes, and results may take years to influence clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients aged 18 years or older diagnosed with skull base osteomyelitis (see definition below) during outpatient consultation or hospitalization at Lariboisière Hospital will be eligible for inclusion in the study, provided that they do not object to participation.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants must meet all of the following criteria: * Age ≥ 18 years. * Diagnosis of skull base osteomyelitis, based on the combination of: * Clinical signs: otorrhea and/or otalgia and/or granulation tissue in the external -auditory canal, headache(s) and/or paralysis of one or more cranial nerves; * AND radiological findings: bone destruction/osteolysis demonstrated on CT scan and/or MRI. Exclusion Criteria: * Participants meeting any of the following criteria will be excluded: Expressed refusal (objection) to participate in the study. Individuals under legal protection measures (guardianship, curatorship, or judicial protection). Patients managed for osteoradionecrosis. Patients managed for squamous cell carcinoma of the external auditory canal.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Central skull base osteomyelitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Lariboisière Hospital, 2 rue Ambroise Paré
Paris, 75010, France